TFRC and Alzheimer disease: Chronic treatment with the cTfRMAb‐TNFR fusion protein, a transferrin receptor mediated BBB‐penetrating biologic TNF‐α inhibitor, reduces neuroinflammation, leading to the restoration of BBB integrity and overall improving cognitive function in a mouse model of AD.[280]